The Medtronic SelectSecure MRI SureScan Model 3830 cardiac lead was the first lead approved for left bundle branch area pacing.
The first patient has been enrolled in a new study of an optimized lead for LBBAP, an area with an explosion of interest in EP as a way to improve patient outcomes.
An advanced algorithm was trained to evaluate more than 100 different details about the inside of a patient's eye. Its ability to identify high-risk patients was comparable to more traditional techniques, exciting researchers.
Long-lesion femoropopliteal peripheral artery disease in a patient's legs as seen in a CT runoff exam. Image courtesy of Canon Medical Systems.
"This research should be a call to health systems, policymakers and other stakeholders to make it easier for patients—especially the most vulnerable patients—to access PAD-specific care," one cardiologist explained.
Maquet Cardiovascular, a subsidiary of Getinge, is recalling two of its endoscopic vessel harvesting devices due to issues with different pieces bending, peeling or detaching during use. Some of the company's other EVH devices were recently involved in a separate recall for similar reasons.
The American Society of Nuclear Cardiology (ASNC) says positron emission tomography (PET) nuclear imaging has seen wider adoption in the past few years, and many cardiac imaging experts say it could become the workhorse technology for nuclear cardiac assessments over the next decade.
The team hopes to develop a model that will estimate a patient's risk of major cardiovascular events and predict when such events are most likely to occur.
Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.
Paradise Ultrasound image courtesy of Recor Medical.
CMS is accepting public comments on the topic for a period of 30 days. Recor Medical and Medtronic have both shared statements in support of the potential policy shift.
The Vanderbilt Transplant Center. Photo by John Russell.
The center's 2024 total of 174 heart transplants represents an increase of 36% compared to 2023, and 10 of the patients receiving a new heart were young children.
Medtronic entered into an exclusive U.S. distribution agreement with Contego Medical for carotid and peripheral vascular disease revascularization products. The agreement includes an option to acquire the full company at a later date.
